Joseph Frattaroli
2021
In 2021, Joseph Frattaroli earned a total compensation of $487.5K as Chief Financial Officer at Inhibikase Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $112,500 |
|---|---|
| Salary | $375,000 |
| Total | $487,500 |
Frattaroli received $375K in salary, accounting for 77% of the total pay in 2021.
Frattaroli also received $112.5K in non-equity incentive plan.
Rankings
In 2021, Joseph Frattaroli's compensation ranked 10,779th out of 12,415 executives tracked by ExecPay. In other words, Frattaroli earned more than 13.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,779 out of 12,415 | 13th |
Division Manufacturing | 4,755 out of 5,505 | 14th |
Major group Chemicals And Allied Products | 2,136 out of 2,375 | 10th |
Industry group Drugs | 1,898 out of 2,096 | 9th |
Industry Biological Products, Except Diagnostic Substances | 418 out of 449 | 7th |
Source: SEC filing on May 5, 2023.
Frattaroli's colleagues
We found one more compensation record of an executive who worked with Joseph Frattaroli at Inhibikase Therapeutics in 2021.
2021
Milton Werner
Inhibikase Therapeutics